Europe Biologics Manufacturing Market Size & Outlook
The biologics manufacturing market in Europe is expected to reach a projected revenue of US$ 38,854.2 million by 2033. A compound annual growth rate of 17% is expected of Europe biologics manufacturing market from 2026 to 2033.
- Biotechnology
- Bioprocessing
- Biologics Manufacturing Market Outlook
- Bioprocessing
Revenue, 2025 (US$M)
$10,827.1
Estimate, 2026 (US$M)
$12,918.5
Forecast, 2033 (US$M)
$38,854.2
CAGR, 2026 - 2033
17.0%
Global Market
Related Markets
Prism AI by Grand View ResearchFree to try
Ask a question about the biologics manufacturing market
Every figure cited from GVR research
Europe biologics manufacturing market highlights
- The Europe biologics manufacturing market generated a revenue of USD 10,827.1 million in 2025.
- The market is expected to grow at a CAGR of 17% from 2026 to 2033.
- In terms of segment, contract manufacturing was the largest revenue generating mode of manufacturing in 2025.
- Contract Manufacturing is the most lucrative mode of manufacturing segment registering the fastest growth during the forecast period.
- Country-wise, Germany is expected to register the highest CAGR from 2026 to 2033.
Europe data book summary
| Market revenue in 2025 | USD 10,827.1 million |
| Market revenue in 2033 | USD 38,854.2 million |
| Growth rate | 17% (CAGR from 2026 to 2033) |
| Largest segment | Contract manufacturing |
| Fastest growing segment | Contract Manufacturing |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Contract Manufacturing, In-house manufacturing |
| Key market players worldwide | Novartis AG, Pfizer Inc, Amgen Inc, Novo Nordisk A/S, AbbVie Inc, Johnson & Johnson, Bristol-Myers Squibb Co, Eli Lilly and Co, F. Hoffmann-La Roche Ltd., WuXi Biologics., FUJIFILM Holdings Corp, Boehringer Ingelheim, Lonza, Samsung BioLogics |
Other key industry trends
- In terms of revenue, Europe region accounted for 27.0% of the global biologics manufacturing market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 33,376.9 million by 2033.
No credit card required*
Publish Date: Sep 17, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biologics Manufacturing Market Scope
Biologics Manufacturing Market segmentation & scope
Others
Biologics Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Johnson & Johnson | View profile | 134,400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | www.jnj.com |
| Amgen Inc | View profile | 26,700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | www.amgen.com |
| AbbVie Inc | View profile | 50,000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | www.abbvieinvestor.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| FUJIFILM Holdings Corp | View profile | 83,784 | 7-3, Akasaka 9-chome, Minato-ku, Tokyo, Japan, 107-0052 | www.fujifilmholdings.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | www.boehringer-ingelheim.com/ |
| Eli Lilly and Co | View profile | 43,000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | www.lilly.com |
| Samsung BioLogics | View profile | 1001-5000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | www.samsungbiologics.com/ |
| Novo Nordisk A/S | View profile | - | - | - |
Europe Biologics Manufacturing Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Biologics Manufacturing Market Outlook will help companies and investors design strategic landscapes.
Contract Manufacturing was the largest segment with a revenue share of 68.71% in 2025.
Horizon Databook has segmented the Europe biologics manufacturing market based on contract manufacturing, in-house manufacturing covering the revenue growth of each sub-segment from 2021 to 2033.
- Europe Biologics Manufacturing Market Mode of Manufacturing Outlook (Revenue, USD Million , 2021-2033)
- Contract Manufacturing
- In-house manufacturing
- Europe Biologics Manufacturing Market Modality Outlook (Revenue, USD Million , 2021-2033)
- Monoclonal Antibodies (mAbs)
- Biosimilar & Recombinant Proteins
- Vaccines (recombinant/mRNA/Viral)
- Cell & Gene Therapies
- RNA-based Therapeutics
- Others
- Europe Biologics Manufacturing Market Disease Indication Outlook (Revenue, USD Million , 2021-2033)
- Oncology
- Autoimmune Disorders
- Infectious Diseases
- Neurological Disorders
- Cardiovascular Disorders
- Other Disease Indications
Reasons to subscribe to Biologics Manufacturing Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Biologics Manufacturing Market Outlook databook
- Our clientele includes a mix of Biologics Manufacturing Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe Biologics Manufacturing Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Europe Biologics Manufacturing Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Europe Biologics Manufacturing Market, 2021-2033 (US$M)
Europe biologics manufacturing market statistics, by mode of manufacturing, 2021-2033 (US$M)
